about
COPD immunopathologyThe relationship between COPD and lung cancerTargeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseaseEpigenome-modifying tools in asthmaBET proteins are a key component of immunoglobulin gene expression.Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.Class II cytokine receptor gene cluster is a major locus for hepatitis B persistenceBET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD.Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD.Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.Overcoming steroid unresponsiveness in airways disease.Epigenetics of asthma.Steroid resistance in severe asthma: current mechanisms and future treatment.Epigenetics in asthma and other inflammatory lung diseases.Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD.Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma.Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD.Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping.Impaired innate immune gene profiling in airway smooth muscle cells from chronic cough patients.New plasmid tools for genetic analysis of Actinobacillus pleuropneumoniae and other pasteurellaceae.Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma.Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation.Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness.
P50
Q26749575-0C0BDFE3-5647-4B84-96F6-12583C2064CEQ26781337-1FF491AE-3F8B-48C4-A2E0-4D3BB8EA43FEQ26786229-DD86EF6B-F301-4FA5-B1F2-E046FCE6D2F3Q28083520-43672DDB-D66E-42DE-8E43-888C86580633Q33811659-121E0E27-6983-45D3-965D-EC0069FC1A33Q34447539-E8299144-4761-4E91-BF60-5280759D8860Q34694885-D6F3C645-D711-4942-A6E9-B0C05AE5D12FQ35580851-E15FB667-A671-488E-A757-C0247E12B266Q35890434-171E5A2A-F6BA-4B90-B459-95598329AF6CQ36297783-0B428397-C83A-4937-9716-6A0AE74A9588Q36426923-0CFBC02C-CD44-4155-98D6-9B274A0EE4FFQ37554612-2C288ABB-02A8-48A4-97D9-79825E998D85Q37852398-104C5DF7-EEC0-4423-B35C-922314D5CCC9Q37853212-AD80B384-B22E-414D-A28B-85DFEC2E7578Q37961760-891BF8D5-CC3B-4673-A310-BFBA8EEA1DD9Q38374957-0A3EA626-DC7A-43C3-832E-2902D66CABCAQ38772942-5EC9CC34-48CE-48A5-9E25-A341B029270EQ38793361-B856E995-636F-4069-9C98-D2D9467AF1BDQ39416033-C8E70146-E4F0-42E2-A114-6D39053E5490Q40069828-DF551640-E481-468C-A1C9-45595C9E39DCQ42570229-4339FEBA-8A31-4908-BC70-776EF7AE23F9Q45923952-CD6C27C7-AC0D-4DF1-B487-DD6DC93C248DQ46312846-C9DF22B2-110F-4E64-B909-2E461BA2135BQ51765103-87E541F1-FFCC-462D-B959-CD15C5A6E371
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew L Durham
@ast
Andrew L Durham
@en
Andrew L Durham
@es
Andrew L Durham
@nl
Andrew L Durham
@sl
type
label
Andrew L Durham
@ast
Andrew L Durham
@en
Andrew L Durham
@es
Andrew L Durham
@nl
Andrew L Durham
@sl
prefLabel
Andrew L Durham
@ast
Andrew L Durham
@en
Andrew L Durham
@es
Andrew L Durham
@nl
Andrew L Durham
@sl
P106
P21
P31
P496
0000-0003-2372-4688